MedTrace Logo

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

NCT07215962 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-10-14

No results posted yet for this study

Summary

The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

BIOLOGICAL

Nivolumab + ipilimumab

According to the product label

BIOLOGICAL

Nivolumab + ipilimumab + platinum-based chemotherapy

According to the product label

BIOLOGICAL

Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy

According to the product label

BIOLOGICAL

Other dual-immuno-oncology therapy with chemotherapy

According to the product label

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-22
Primary Completion
2025-07-01
Completion
2026-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07215962 on ClinicalTrials.gov